| Term es nes pval sidak fdr geneset_size leading_edge leading_edge_size |
| Oxysterols derived from cholesterol 0.8689267118772837 2.226317843729809 0.025992899096648 0.9999998306532532 1.0 7 Q9UBM7 1 |
| Cholesterol biosynthesis with skeletal dysplasias 0.8581507614695956 2.2015033522809873 0.0277004096376223 0.9999999400677136 1.0 6 Q9UBM7,Q14739,Q15392 3 |
| 7oxoc and 7betahc pathways 0.8049399428540728 1.934103031509422 0.0531004612830734 0.9999999999999908 1.0 9 Q9UBM7 1 |
| Kennedy pathway from sphingolipids 0.8487289815321213 1.904790987515631 0.0568072458803974 0.9999999999999992 1.0 4 P35790 1 |
| Metabolism of spingolipids in er and golgi apparatus 0.8087477439745652 1.7496482039813908 0.0801790364507435 1.0 1.0 4 Q06136,Q16739 2 |
| Pregnane x receptor pathway 0.7554367406097766 1.6589735831813264 0.0971211155893654 1.0 1.0 5 Q06520 1 |
| Allograft rejection 0.7310362615320739 1.646280192542954 0.0997060855568614 1.0 1.0 8 Q9BY49,P04439,P10321,P42224,P08183,P08670 6 |
| Ketogenesis and ketolysis 0.7796775682908831 1.6355765625113077 0.1019282388919546 1.0 1.0 4 O43772 1 |
| Sphingolipid metabolism overview 0.7110154927365803 1.5619725194593312 0.1182944628078539 1.0 1.0 8 Q13510,Q06136,Q16739,Q96G23 4 |
| Sphingolipid metabolism integrated pathway 0.7110154927365803 1.5619725194593312 0.1182944628078539 1.0 1.0 8 Q13510,Q06136,Q16739,Q96G23 4 |
| 1q211 copy number variation syndrome 0.6993774451196612 1.548390635038542 0.1215282745859518 1.0 1.0 6 Q9NPH0,Q07157 2 |
| Sphingolipid metabolism in senescence 0.7115730313046401 1.5290000488951747 0.1262644317980439 1.0 1.0 10 Q13510,Q06136,Q16739,Q96G23 4 |
| Sphingolipid pathway 0.706405602524763 1.5247747903664404 0.1273152798332639 1.0 1.0 9 Q13510,Q06136,Q16739,Q96G23 4 |
| Statin inhibition of cholesterol production 0.837841961491098 1.5223283413586972 0.127926830102073 1.0 1.0 3 Q8WTV0 1 |
| Type ii interferon signaling ifng 0.7138518004200891 1.4887367332055372 0.1365567080515939 1.0 1.0 5 P42224,Q06124 2 |
| Cancer immunotherapy by pd1 blockade 0.8230851770078658 1.4660741588732833 0.1426280847699081 1.0 1.0 3 Q06124 1 |
| Metapathway biotransformation phase i and ii 0.7240940211757719 1.410847163070203 0.158289684501198 1.0 1.0 20 Q86UY6,Q06520,P07099,P34913,Q16850,O15217 6 |
| Familial hyperlipidemia type 3 0.960986382039014 1.3983595410138157 0.1620051263172977 1.0 1.0 2 Q8WTV0 1 |
| Photodynamic therapyinduced nfe2l2 nrf2 survival signaling 0.7124935133225601 1.3687639927954 0.1710730596562384 1.0 1.0 4 P07099 1 |
| Influence of laminopathies on wnt signaling 0.6625479806985354 1.355685779734023 0.1751991658228755 1.0 1.0 8 Q5JTV8,P48729,O75844,O60725 4 |
| Wntbetacatenin signaling pathway in leukemia 0.793446244477173 1.3528585490452296 0.1761008238617585 1.0 1.0 3 P35222,P48729 2 |
| Drug induction of bile acid pathway 0.94884063305116 1.3527173387415103 0.1761459490835815 1.0 1.0 2 Q06520 1 |
| 15q112 copy number variation syndrome 0.7024143431226785 1.3284761054005356 0.1840208721899001 1.0 1.0 4 Q7L576 1 |
| Familial hyperlipidemia type 4 0.7768509669110993 1.2894209674132142 0.1972517759079086 1.0 1.0 3 Q07954 1 |
| Il10 antiinflammatory signaling pathway 0.6589313099372803 1.2613473983022234 0.2071837111582861 1.0 1.0 5 P42224 1 |
| Cholesterol metabolism with bloch and kandutschrussell pathways 0.684053819640151 1.2430269054191434 0.2138579189979661 1.0 1.0 20 Q9UBM7,Q14739,Q15392,Q16850 4 |
| Heart development 0.7646251173064017 1.2427094427737515 0.2139749230023429 1.0 1.0 3 Q06124 1 |
| Proteoglycan biosynthesis 0.9171880750828124 1.2341161137541754 0.2171596398764541 1.0 1.0 2 Q8NCH0 1 |
| Overlap between signal transduction pathways contributing to lmna laminopathies 0.6482349970350315 1.2251538864973903 0.2205172451980277 1.0 1.0 12 Q9Y2U8,P55209,O60725,P48729,O75844 5 |
| Complement and coagulation cascades 0.7590474139326037 1.2214136249596994 0.2219294510303546 1.0 1.0 3 P10909 1 |
| Histone modifications 0.6270185864842783 1.2204826935039468 0.2222819462678642 1.0 1.0 7 Q03164,Q9H7B4 2 |
| Genes controlling nephrogenesis 0.6222992673224796 1.2176410054611004 0.2233604246813838 1.0 1.0 6 P35222,O94813 2 |
| Interactome of polycomb repressive complex 2 prc2 0.7518409425625928 1.1939192364556193 0.2325095619683828 1.0 1.0 3 Q15022,Q9NYF8 2 |
| Regulation of wnt bcatenin signaling by small molecule compounds 0.6685575444270752 1.1929943757477814 0.232871575730686 1.0 1.0 4 P48729,Q07954 2 |
| Immune response to tuberculosis 0.9009937430990068 1.1737414211313526 0.2404986138001448 1.0 1.0 2 P42224 1 |
| Development of ureteric collection system 0.6573606632686759 1.1482139637153392 0.2508802461561989 1.0 1.0 4 P35222,O94813 2 |
| Tgfbeta receptor signaling in skeletal dysplasias 0.6315481477788984 1.1474619533802255 0.2511907488983234 1.0 1.0 5 P62942,P42224 2 |
| Tgfbeta receptor signaling 0.6315481477788984 1.1474619533802255 0.2511907488983234 1.0 1.0 5 P62942,P42224 2 |
| Constitutive androstane receptor pathway 0.6097585307908251 1.145983060821914 0.2518021610211045 1.0 1.0 7 Q06520 1 |
| Vitamin d receptor pathway 0.6194591937694875 1.1361148484605046 0.2559085014813242 1.0 1.0 10 Q06520,Q5VV42,P08183,Q96KA5,Q92783 5 |
| Disruption of postsynaptic signaling by cnv 0.5963148777325946 1.087933685613153 0.2766243838714208 1.0 1.0 7 Q7L576,Q14168,Q06787 3 |
| Cytosine methylation 0.6103651772897063 1.059444595632034 0.2893973489628925 1.0 1.0 5 P48735 1 |
| Ethanol effects on histone modifications 0.6032294938025101 1.0496541759820457 0.2938771391504227 1.0 1.0 11 P00374 1 |
| Mitochondrial long chain fatty acid betaoxidation 0.6103601112090952 1.030163143794818 0.3029334278229214 1.0 1.0 14 P11310,O43772 2 |
| Il4 signaling pathway 0.586590910538967 1.0289225592946984 0.3035160665576093 1.0 1.0 8 Q06124 1 |
| Familial partial lipodystrophy fpld 0.573531600452213 1.0067082646420034 0.3140749893496628 1.0 1.0 6 O60725 1 |
| Complement system in neuronal development and plasticity 0.5872641969740003 0.9981105808940568 0.318225739894763 1.0 1.0 10 Q9NR28,P10909,Q5KU26 3 |
| Familial hyperlipidemia type 1 0.8490982701509038 0.9826896294343932 0.3257602163128057 1.0 1.0 2 Q07954 1 |
| Familial hyperlipidemia type 5 0.8490982701509038 0.9826896294343932 0.3257602163128057 1.0 1.0 2 Q07954 1 |
| Hepatitis c and hepatocellular carcinoma 0.5812622864888216 0.9724503568374144 0.3308265503651779 1.0 1.0 10 P38398,P31350,Q14247,P62993,P63000,P04637,Q06124 7 |
| Type i collagen synthesis in the context of osteogenesis imperfecta 0.5806747052644945 0.9533711992168894 0.3404020285517397 1.0 1.0 11 O75718,P13674,Q32P28 3 |
| Il2 signaling pathway 0.5699477579724725 0.9407373962593396 0.3468394498246239 1.0 1.0 9 Q06124 1 |
| Adipogenesis 0.5753350321097327 0.9306500849436816 0.3520345975496539 1.0 1.0 11 P42224,O75844,P43490 3 |
| S1p receptor signal transduction 0.5557430869602231 0.9132805325941928 0.3610950182606254 1.0 1.0 7 Q13510,Q9H0H5,P04899 3 |
| Fluoropyrimidine activity 0.5638244240993877 0.8981306128186161 0.3691159201709091 1.0 1.0 10 P00374,Q92820,P18074 3 |
| Urea cycle and related diseases 0.8159735001840289 0.8637050546682788 0.3877499362014167 1.0 1.0 2 Q9Y619 1 |
| Corticotropinreleasing hormone signaling pathway 0.5707898571699002 0.8470031845919189 0.3969933464015565 1.0 1.0 15 P42892 1 |
| Il6 signaling pathway 0.5426973165410733 0.8087680860770952 0.4186485564246585 1.0 1.0 10 Q06124 1 |
| Ccl18 signaling pathway 0.5292352267958467 0.8003643506911091 0.4234997292991331 1.0 1.0 7 Q86UE4,P42224,P08670 3 |
| Mitochondrial complex iii assembly 0.5318891466713149 0.7634551203264304 0.4451920179568378 1.0 1.0 10 Q6DKK2,O14949,Q9BRT2,Q9UDW1 4 |
| Cholesterol biosynthesis pathway 0.5366912915595907 0.7520228212002688 0.4520373348994204 1.0 1.0 12 Q9UBM7 1 |
| Nuclear receptors in lipid metabolism and toxicity 0.7810084652189946 0.7418829491442054 0.4581582574428147 1.0 1.0 2 P08183 1 |
| Purinergic signaling 0.6303429310198605 0.7413568660764334 0.4584770905281154 1.0 1.0 3 P04899 1 |
| Nanomaterial induced apoptosis 0.5064848587990778 0.7206979699069971 0.4710953617248892 1.0 1.0 6 Q9NR28,O95831 2 |
| Folate metabolism 0.5420552486446424 0.7126426948461458 0.4760668851314631 1.0 1.0 16 Q8WTV0,P00374 2 |
| Thyroid hormones production and peripheral downstream signaling effects 0.5189672965262819 0.6942881639097345 0.4875015121921935 1.0 1.0 11 P62753,O60343,P35222,O60341,P62993,P04637 6 |
| Complement system 0.5122917902968985 0.6822282035230892 0.4950946635264521 1.0 1.0 10 P48729,Q99829,P04899,P26885 4 |
| Tlr4 signaling and tolerance 0.5114674966341508 0.6578120052844268 0.510658939134943 1.0 1.0 5 Q15629,Q9UHD2 2 |
| Oncostatin m signaling pathway 0.5135607231979971 0.6569519432918186 0.5112118172502274 1.0 1.0 12 Q06124 1 |
| Robo4 and vegf signaling pathways crosstalk 0.7445712182554323 0.6205309132728777 0.5349083082078554 1.0 1.0 2 O94813 1 |
| Praderwilli and angelman syndrome 0.516230508539433 0.6021303067224286 0.5470874023085464 1.0 1.0 4 P04637,Q7L576 2 |
| Il9 signaling pathway 0.4732939879852742 0.5692883766615898 0.5691604535059904 1.0 1.0 7 P42224 1 |
| Fatty acid betaoxidation 0.5131755460580919 0.5678377546223312 0.57014514101808 1.0 1.0 18 P11310,O43772 2 |
| Rala downstream regulated genes 0.4854328441652233 0.557892857203729 0.5769175493065308 1.0 1.0 5 P16989,P11233 2 |
| H19 action rbe2f1 signaling and cdkbetacatenin activity 0.502397874360021 0.5526983812186609 0.580469962011239 1.0 1.0 4 P11802,P35222 2 |
| Ciliopathies 0.4970124428153722 0.5330929665253757 0.5939692276092203 1.0 1.0 16 Q10713,O43924,Q15555,Q13432 4 |
| Progeriaassociated lipodystrophy 0.4706690811121711 0.5297011076414834 0.5963191798674059 1.0 1.0 9 O60725 1 |
| Male infertility 0.5100784023090046 0.5280473289639379 0.597466486771044 1.0 1.0 20 P41440,Q15165,P10909 3 |
| Insulin signaling in adipocytes normal condition 0.5637236598097107 0.5146269291053656 0.6068137435564958 1.0 1.0 3 P62753 1 |
| Insulin signaling in adipocytes diabetic condition 0.5637236598097107 0.5146269291053656 0.6068137435564958 1.0 1.0 3 P62753 1 |
| Microrna network associated with chronic lymphocytic leukemia 0.7085020242915021 0.5077945091892134 0.6115974608878334 1.0 1.0 2 Q07820 1 |
| Pparalpha pathway 0.4600493299482044 0.5025567504933997 0.6152759432462576 1.0 1.0 8 P11310 1 |
| Degradation pathway of sphingolipids including diseases 0.4524214801406707 0.5013991945819741 0.616090206524651 1.0 1.0 6 P16278,P17900,P06280 3 |
| Mitochondrial fatty acid synthesis pathway 0.5592783505154655 0.5004546862405973 0.616754955333422 1.0 1.0 3 Q9BV79,Q13085 2 |
| Fatty acid transporters 0.4698565733912574 0.5001053838985858 0.6170008753736718 1.0 1.0 5 P33121,Q01469 2 |
| Gdnfret signaling axis 0.5581119237057124 0.496759769791596 0.6193584680505808 1.0 1.0 3 O94813 1 |
| Endochondral ossification with skeletal dysplasias 0.4539849009321013 0.4932296667206138 0.6218503181312995 1.0 1.0 7 Q96QD8 1 |
| Endochondral ossification 0.4539849009321013 0.4932296667206138 0.6218503181312995 1.0 1.0 7 Q96QD8 1 |
| Interferon type i signaling pathways 0.4813933285696903 0.487039150226652 0.6262305869133447 1.0 1.0 15 P42224,Q99873,P46108,Q53EL6,P63000,Q06124 6 |
| Neuroinflammation 0.5377406319222027 0.4339267288051486 0.6643416493368153 1.0 1.0 3 P00403 1 |
| Glycerophospholipid biosynthetic pathway 0.4645391100229085 0.4244445436552231 0.671241641160893 1.0 1.0 4 O00116,P48651 2 |
| T cell receptor and costimulatory signaling 0.6720647773279399 0.4033501291309002 0.6866906688940424 1.0 1.0 2 P48729 1 |
| Gastric cancer network 2 0.4498206727489482 0.383714435080998 0.7011901125019429 1.0 1.0 14 Q86UE4,Q8TDN6,Q14739,Q9HB71 4 |
| Omega9 fatty acid synthesis 0.4366249078850436 0.3832263755142301 0.7015519232662 1.0 1.0 5 O95573,O95864,P33121,O60488 4 |
| Thymic stromal lymphopoietin tslp signaling pathway 0.437232223420033 0.3768582393542135 0.7062789573119961 1.0 1.0 11 Q06124 1 |
| Proximal tubule transport 0.419580295838827 0.3521761749673524 0.7247061434437159 1.0 1.0 8 P08183 1 |
| Cardiac progenitor differentiation 0.6448288553551763 0.3326837619387686 0.7393730081099406 1.0 1.0 2 Q16539 1 |
| Joubert syndrome 0.4383129837823918 0.3311182806787851 0.7405551437931472 1.0 1.0 15 O43924,Q13432 2 |
| Target of rapamycin tor signaling 0.4206644517333753 0.3308411359317707 0.740764486945523 1.0 1.0 5 P62942 1 |
| Type i interferon induction and signaling during sarscov2 infection 0.4109909006641304 0.2663620187088055 0.7899604135695981 1.0 1.0 4 P42224 1 |
| Sars coronavirus and innate immunity 0.4743615677796939 0.2629867334617657 0.7925608044741617 1.0 1.0 3 P42224 1 |
| Camkk2 pathway 0.3949677463465789 0.2463544334053415 0.8054078762351193 1.0 1.0 10 O76024 1 |
| Sudden infant death syndrome sids susceptibility pathways 0.4425579259822857 0.2229077109140274 0.8236073349309292 1.0 1.0 26 P42892,P10644 2 |
| Modulators of tcr signaling and t cell activation 0.3781860592535138 0.216237355447875 0.828802736838969 1.0 1.0 8 O96000 1 |
| Mitochondrial complex i assembly model oxphos system 0.4231757973036221 0.2160773872590984 0.8289274257117833 1.0 1.0 21 P03886,O43676,O96000,Q96CU9 4 |
| Gaba receptor signaling 0.3789565967895647 0.2082939977956386 0.8349994179374443 1.0 1.0 5 P53680 1 |
| Extracellular vesiclemediated signaling in recipient cells 0.4466126656848325 0.2021338750358156 0.8398120659685551 1.0 1.0 3 P35222,P42345 2 |
| Nitric oxide metabolism in cystic fibrosis 0.3765659543109797 0.2019777116085178 0.839934148639305 1.0 1.0 5 Q99873,O60678,O14744,O95865 4 |
| Glycosaminoglycan degradation 0.3752229733010614 0.1984657219710091 0.842680701200879 1.0 1.0 5 P15586,P16278 2 |
| Estrogen signaling pathway 0.4436671575846849 0.1962300227990805 0.8444301300514852 1.0 1.0 3 P28482,Q16539 2 |
| Tumor suppressor activity of smarcb1 0.379861723010625 0.1903705105348827 0.8490188042763147 1.0 1.0 11 O14497,Q969G3,Q15022,Q8TAQ2,Q12824 5 |
| Hematopoietic stem cell gene regulation by gabp alphabeta complex 0.4249195229653104 0.161229759188814 0.8719124432853951 1.0 1.0 3 Q07820 1 |
| Factors and pathways affecting insulinlike growth factor igf1akt signaling 0.3596168017686093 0.1596186078901625 0.8731815199476016 1.0 1.0 5 P06730,P49770,P42345,Q13418 4 |
| Ncrnas involved in wnt signaling in hepatocellular carcinoma 0.3539352253263533 0.1383884874006584 0.8899333951946964 1.0 1.0 9 P67870,Q86UE4,P48729,P35222 4 |
| Pdgf pathway 0.3604756559131137 0.1373978539988366 0.8907163272225616 1.0 1.0 11 Q06124 1 |
| Vitamin b6dependent and responsive disorders 0.5406698564593373 0.1332116887829386 0.8940259669238917 1.0 1.0 2 P49419 1 |
| Tcell receptor tcr signaling pathway 0.3679833369657869 0.1301159787116854 0.896474668407875 1.0 1.0 14 Q06124,P46108,P62993,P08670 4 |
| Epithelial to mesenchymal transition in colorectal cancer 0.3634876892736368 0.1274649908161385 0.8985723804063042 1.0 1.0 13 O75340,P35222,P14923,Q07157,P62993,P04637,Q15022 7 |
| Hippo signaling regulation pathways 0.3492837273668311 0.1013067367449787 0.9193069685606684 1.0 1.0 12 P10644 1 |
| Erk pathway in huntingtons disease 0.5104895104895182 0.0976228426978142 0.9222317852926858 1.0 1.0 2 P42858 1 |
| Apoptosis modulation and signaling 0.3512472292232601 0.0899268030016677 0.9283453817232364 1.0 1.0 14 Q9NR28,Q07820,O95831 3 |
| Met in type 1 papillary renal cell carcinoma 0.3577423454922102 0.0813474365465807 0.9351656500545736 1.0 1.0 17 Q06124,Q92733,O43815 3 |
| Mirna regulation of prostate cancer signaling pathways 0.3171911256204311 0.0759473622909562 0.939460975980994 1.0 1.0 6 P35222,P62993 2 |
| Dna mismatch repair 0.3507217569719763 0.0662497571107694 0.9471789833081872 1.0 1.0 17 Q9UQ84 1 |
| Ferroptosis 0.3688186598224673 0.0609890535216142 0.9513679268516037 1.0 1.0 23 P02786,Q15043,Q96QD8,P09601,P08195 5 |
| Preimplantation embryo 0.3097598732261672 0.0536015570276838 0.9572526159686904 1.0 1.0 7 Q9P0M6,Q92945,Q99729 3 |
| Dopamine metabolism 0.4435038645565025 0.0494879749908059 0.9605304200260204 1.0 1.0 2 P21964 1 |
| Nicotine effect on dopaminergic neurons 0.2883977900552554 0.0483612560142392 0.9614283363766544 1.0 1.0 4 P17612,P62136,P63096 3 |
| Mirna biogenesis 0.4372469635627597 0.0467742441745553 0.9626931567302932 1.0 1.0 2 Q9HAV4 1 |
| Osteoblast differentiation and related diseases 0.3057980315388103 0.0460093428488763 0.9633028032804384 1.0 1.0 7 P35222,P42224 2 |
| Mirna regulation of p53 pathway in prostate cancer 0.3173784977908709 0.043539912088789 0.965271149431089 1.0 1.0 3 P04637,O96017 2 |
| Mammary gland development pathway involution stage 4 of 4 0.317378497790871 0.043539912088789 0.965271149431089 1.0 1.0 3 P40763,P04637 2 |
| Agerage pathway 0.3249874174456935 0.0426676617206672 0.9659664582909984 1.0 1.0 13 P42224 1 |
| Pathways of nucleic acid metabolism and innate immune sensing 0.2918395818679294 0.0356640672600787 0.9715502224860546 1.0 1.0 5 O00584 1 |
| Network map of sarscov2 signaling pathway 0.350926080372705 0.0327591188641886 0.973866679121538 1.0 1.0 22 Q9H269,Q07021,P42224,Q99829,P31350,P63000,Q08380,Q14240,Q9UHD2,Q96J02 10 |
| Prostaglandin and leukotriene metabolism in senescence 0.2798232695139934 0.029109579318985 0.9767771958448924 1.0 1.0 3 P09960,P63096 2 |
| Tp53 network 0.3172616856827472 0.0265516866345304 0.9788173081385448 1.0 1.0 2 P04637 1 |
| Hostpathogen interaction of human coronaviruses interferon induction 0.2917027521178689 0.0212586824094404 0.98303930304454 1.0 1.0 7 Q9UHD2,P42224 2 |
| Mesodermal commitment pathway 0.3256163484075464 0.0131220222689271 0.9895304414804368 1.0 1.0 18 Q9Y2X9,Q07021,P10644,Q16204,Q8IWS0,Q96EB1 6 |
| Netrinunc5b signaling pathway 0.3063323038684426 0.0105922247034349 0.9915487854758548 1.0 1.0 13 Q06124 1 |
| Oxidative phosphorylation 0.3432354976134326 0.0074959271144273 0.994019171495933 1.0 1.0 24 P03886,Q15904 2 |
| Biomarkers for pyrimidine metabolism disorders 0.2824483775811288 0.0069125758245183 0.9944846063985956 1.0 1.0 7 P11172,Q9Y606,P04818,P31350,P12277,P23921 6 |
| Translation factors 0.3831477845997416 0.0045362811408886 0.9963805837275268 1.0 1.0 36 O75153 1 |
|
|
